>   Structural Summary
100% seqID Fv Structure5b8c [Fvs: BA, ED, HG, KJ], 5dk3 [Fvs: BA, GF], 5ggs [Fvs: AB, CD], 5jxe [Fvs: DC, GF]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
Highest Clinical Trial (May '24)Approved
Estimated Status (May '24)Active
Recorded Developmental Technology
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedAduro BioTech, AIO Studien gGmbH, Amgen, Augusta University, Bayer, BerGenBio, Big Ten Cancer Research Consortium, BioLineRx, Canadian Cancer Trials Group, Celgene Corporation, Columbia University, Dana-Farber Cancer Institute, DNAtrix, Duke University, Eisai Co Ltd, Eli Lilly, Emory University, Fox Chase Cancer Center, Genexine, Gilead Sciences, H. Lee Moffitt Cancer Center and Research Institute, Hoosier Cancer Research Network, Icahn School of Medicine at Mount Sinai, ImmunoGen, Incyte Corporation, Institut fuer Frauengesundheit, Institute of Cancer Research, M. D. Anderson Cancer Center, Massachusetts General Hospital, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Merck & Co, Merck Sharp & Dohme, National Cancer Center Hospital East, National Cancer Institute (France), National Cancer Institute (USA), Netherlands Cancer Institute, Northwestern University, NYU Langone Medical Center, Oslo University Hospital, Plexxikon, Providence Health & Services, Royal Marsden NHS Foundation Trust, Sarcoma Alliance for Research through Collaboration, Sellas Life Sciences Group, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Spanish Breast Cancer Research Group, Syndax Pharmaceuticals, TG Therapeutics Inc, University Health Network, University of Alabama, University of Birmingham, University of California at Los Angeles, University of California at San Francisco, University of California San Diego, University of Colorado at Denver, University of Miami, University of Pittsburgh, University of Utah, University of Washington, Verastem Oncology, Wakayama Medical University, Washington University School of Medicine, Yale University, The Leukemia & Lymphoma Society
Conditions ApprovedCervical cancer, Colorectal cancer, Diffuse large B cell lymphoma, Gastric cancer, Head and neck cancer, Hodgkin's disease, Liver cancer, Malignant melanoma, Non-small cell lung cancer, Pancreatic cancer, Solid tumours, Urogenital cancer, Cancer, Merkel cell carcinoma, Renal cell carcinoma
Conditions ActiveSmall cell lung cancer, Bladder cancer, Breast cancer, Endometrial cancer, Fallopian tube cancer, Gastrointestinal cancer, Mesothelioma, Multiple myeloma, Nasopharyngeal cancer, Oesophageal cancer, Ovarian cancer, Peritoneal cancer, Prostate cancer, Squamous cell cancer, Acute myeloid leukaemia, Adenoid cystic carcinoma, Bone cancer, Brain metastases, Cholangiocarcinoma, Follicular lymphoma, Germ cell and embryonal neoplasms, Glioblastoma, Glioma, Inflammatory breast cancer, Liver metastases, Lymphoma, Meningioma, Myelodysplastic syndromes, Neuroendocrine tumours, Non-Hodgkin's lymphoma, Osteosarcoma, Penile cancer, Rectal cancer, Recurrent respiratory papillomatosis, Sarcoma, Soft tissue sarcoma, Thymoma, Thyroid cancer, Uveal melanoma, Chronic lymphocytic leukaemia, Haematological malignancies, Leiomyosarcoma, Mantle-cell lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma, T-cell lymphoma, Gliosarcoma, Human papillomavirus infections
Conditions Discontinuedna
NotesPembrolizumab is the new name for Lambrolizumab (PL110)

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy